We can’t show the full text here under this license. Use the link below to read it at the source.
Risk of depression with GLP ‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study
Risk of depression linked to GLP-1 receptor agonist use in overweight or obese adults with type 2 diabetes
AI simplified
Abstract
GLP-1 receptor agonist use was associated with a 2.2% higher incidence of depression compared to in a cohort of 51,408 patients.
- Overall depression incidence was 17.0% in GLP-1 RA users versus 14.8% in SGLT2i users.
- The hazard ratio for increased depression risk with GLP-1 RAs compared to SGLT2is was 1.09.
- The association with increased depression risk was stronger in adults aged 65 years and older, with a hazard ratio of 1.15.
- The increased risk of depression plateaued after approximately 6 months of treatment.
- In secondary analysis, GLP-1 RA use was linked to a lower rate of all-cause mortality, with a hazard ratio of 0.74.
AI simplified
Key numbers
1.09
Increase in Depression Risk
Hazard ratio comparing GLP-1 RA to SGLT2i users.
2.2%
Absolute Risk Difference
Absolute risk difference over one year.
17.0%
Depression Incidence
Incidence of depression in GLP-1 RA group.